Pharmacokinetic Considerations in Prescribing Antiepileptic Drugs
- 1 August 2001
- Vol. 42 (s4) , 19-23
- https://doi.org/10.1111/j.1528-1167.2001.00004.x
Abstract
Summary: Each antiepileptic drug has a characteristic pharmacokinetic profile, and the unique properties of each must be considered when selecting the optimal agent for a particular patient. Detailed pharmacologic data are obtained during the preapproval evaluation of a drug, particularly in early phase studies in healthy volunteers. Each drug is then evaluated in the target population in later phase trials and in certain populations, such as children and individuals with various types of organ failure. Key considerations are bioavailability, protein binding, metabolism and elimination, and drug interactions. Important pharmacokinetic considerations in the selection and use of these drugs are presented in this review, with examples from currently available drugs.Keywords
This publication has 11 references indexed in Scilit:
- Pharmacokinetic profile of levetiracetamPharmacology & Therapeutics, 2000
- The Clinical Pharmacokinetics of the New Antiepileptic DrugsEpilepsia, 1999
- FelbamateEpilepsia, 1999
- VigabatrinEpilepsia, 1999
- ZonisamideEpilepsia, 1999
- Metabolism and excretion of mood stabilizers and new anticonvulsants.Cellular and Molecular Neurobiology, 1999
- Pharmacokinetics of antiepileptic drugsNeurology, 1998
- Guidelines for the care of women with epilepsyNeurology, 1998
- GabapentinDrugs, 1993
- Effects of Pregnancy on Antiepileptic Drug UtilizationEpilepsia, 1985